Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome

References

• United States Cancer Statistics: 1999–2007 incidence and mortality web-based reportAtlanta, GACenters for Disease Control and Prevention Available from: http://apps.nccd.cdc.gov/uscs/Accessed April 16, 2012
   Google Scholar
• MaXDoesMRazaAMayneSTMyelodysplastic syndromes: incidence and survival in the United StatesCancer200710981536154217345612
   PubMed Web of Science ®Google Scholar
• US Census BureauCurrent Population Reports1193
   Google Scholar
• SteensmaDPHeptinstallKVJohnsonVMCommon troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large Internet-based surveyLeuk Res200832569169818054795
   PubMed Web of Science ®Google Scholar
• JansenAJEssink-BotMLBeckersEAHopWCSchipperusMRVan RhenenDJQuality of life measurement in patients with transfusion-dependent myelodysplastic syndromesBr J Haematol2003121227027412694248
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUHofbauerLCEhningerGHoligKThe clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromesLeuk Res1312012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Hellstrom-LindbergEGulbrandsenNLindbergGA validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of lifeBr J Haematol200312061037104612648074
   PubMed Web of Science ®Google Scholar
• SeymourJFFenauxPSilvermanLREffects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromesCrit Rev Oncol Hematol201076321822720451404
   PubMed Web of Science ®Google Scholar
• SekeresMASchoonenWMKantarjianHCharacteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveysJ Natl Cancer Inst2008100211542155118957672
   PubMedGoogle Scholar
• BurnettAKMilliganDPrenticeAGA comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer200710961114112417315155
   PubMed Web of Science ®Google Scholar
• ShihAHLevineRLMolecular biology of myelodysplastic syndromesSemin Oncol201138561362021943667
   PubMed Web of Science ®Google Scholar
• GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood1997896207920889058730
   PubMed Web of Science ®Google Scholar
• JiangYDunbarAGondekLPAberrant DNA methylation is a dominant mechanism in MDS progression to AMLBlood200911361315132518832655
   PubMed Web of Science ®Google Scholar
• WardAJCooperTAThe pathobiology of splicingJ Pathol2010220215216319918805
   PubMed Web of Science ®Google Scholar
• YoshidaKSanadaMShiraishiYFrequent pathway mutations of splicing machinery in myelodysplasiaNature20114787367646921909114
   PubMed Web of Science ®Google Scholar
• VisconteVMakishimaHJankowskaASF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblastsLeukemia201226354254521886174
   PubMed Web of Science ®Google Scholar
• PapaemmanuilECazzolaMBoultwoodJSomatic SF3B1 mutation in myelodysplasia with ring sideroblastsN Engl J Med2011365151384139521995386
   PubMed Web of Science ®Google Scholar
• DammFKosmiderOGelsi-BoyerVMutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromesBlood2012119143211321822343920
   PubMed Web of Science ®Google Scholar
• JaderstenMSaftLSmithATP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progressionJ Clin Oncol201129151971197921519010
   PubMed Web of Science ®Google Scholar
• KoMHuangYJankowskaAMImpaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Nature2010468732583984321057493
   PubMed Web of Science ®Google Scholar
• JankowskaAMMakishimaHTiuRVMutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3ABlood2011118143932394121828135
   PubMed Web of Science ®Google Scholar
• HarriesLWHernandezDHenleyWHuman aging is characterized by focused changes in gene expression and deregulation of alternative splicingAging Cell201110586887821668623
   PubMed Web of Science ®Google Scholar
• ForsbergLARasiCRazzaghianHRAge-related somatic structural changes in the nuclear genome of human blood cellsAm J Hum Genet201290221722822305530
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer200610681794180316532500
   PubMed Web of Science ®Google Scholar
• LubbertMSuciuSBailaLLow-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study GroupJ Clin Oncol201129151987199621483003
   PubMed Web of Science ®Google Scholar
• SteensmaDPBaerMRSlackJLMulticenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialJ Clin Oncol200927233842384819528372
   PubMed Web of Science ®Google Scholar
• KantarjianHOkiYGarcia-ManeroGResults of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood20071091525716882708
   PubMed Web of Science ®Google Scholar
• SilvermanLRMcKenzieDRPetersonBLFurther analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group BJ Clin Oncol200624243895390316921040
   PubMed Web of Science ®Google Scholar
• KornblithABHerndonJE2ndSilvermanLRImpact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B studyJ Clin Oncol200220102441245212011121
   PubMed Web of Science ®Google Scholar
• ItzyksonRThepotSQuesnelBPrognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineBlood2011117240341120940414
   PubMed Web of Science ®Google Scholar
• FenauxPGattermannNSeymourJFProlonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-CBr J Haematol2010149224424920136825
   PubMed Web of Science ®Google Scholar
• KantarjianHO’BrienSCortesJResults of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeCancer200610651090109816435386
   PubMed Web of Science ®Google Scholar
• MarcucciGSilvermanLEllerMLintzLBeachCLBioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromesJ Clin Pharmacol200545559760215831784
   PubMed Web of Science ®Google Scholar
• LyonsRMCosgriffTMModiSSHematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromesJ Clin Oncol200927111850185619255328
   PubMed Web of Science ®Google Scholar
• GarciaRde MiguelDBailenADifferent clinical results with the use of different dosing schedules of azacitidine in patients with myelodysplastic syndrome managed in community-based practice: effectiveness and safety data from the Spanish azacitidine compassionate use registry (Abstract 2773)Blood200914422
   Google Scholar
• Garcia-ManeroGGoreSDCogleCPhase I study of oral azacitidine in myelodysplastic sydromes, chronic myelomonocytic leukemia and acute myeloid leukemiaJ Clin Oncol201129182521252721576646
   PubMed Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group BJ Clin Oncol200220102429244012011120
   PubMed Web of Science ®Google Scholar
• SantiniVFenauxPMuftiGJManagement and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Eur J Haematol201085213013820394651
   PubMed Web of Science ®Google Scholar
• ItzyksonRThepotSBeyne-RauzyODoes addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?Leuk Res201136439740022177456
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFJGreenbergPLPhase 2 study of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyBlood2010116173163317020631375
   PubMed Web of Science ®Google Scholar
• ListAKurtinSRoeDJEfficacy of lenalidomide in myelodysplastic syndromesN Engl J Med2005352654955715703420
   PubMed Web of Science ®Google Scholar
• ListADewaldGBennettJLenalidomide in the myelodysplastic syndrome with chromosome 5q deletionN Engl J Med2006355141456146517021321
   PubMed Web of Science ®Google Scholar
• MustoPMaurilloLSpagnoliAAzacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient programCancer201011661485149420151429
   PubMed Web of Science ®Google Scholar
• GrovdalMKarimiMKhanRMaintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapyBr J Haematol2010150329330220497178
   PubMed Web of Science ®Google Scholar
• BraitehFSorianoAOGarcia-ManeroGPhase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancersClin Cancer Res200814196296630118829512
   PubMed Web of Science ®Google Scholar
• SekeresMAListAFCuthbertsonDPhase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromesJ Clin Oncol201028132253225820354132
   PubMed Web of Science ®Google Scholar
• SekeresMAO’KeefeCListAFDemonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromesAm J Hematol201186110210321080340
   PubMed Web of Science ®Google Scholar
• PollyeaDAKohrtHEGallegosLSafety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemiaLeukemia10282011 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar